小细胞肺癌细胞依赖KIF11生存
Yuji Sakuma1, Sachie Hirai1, Miki Yamaguchi1
1Department of Molecular Medicine, Research Institute for Immunology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
International journal of molecular sciences
|July 13, 2024
概括
针对基因素家族成员11 (KIF11) 的向显示出治疗小细胞肺癌 (SCLC) 的前景. 抑制KIF11,尤其是BCL2L1,显著降低了SCLC细胞的活力和生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 小细胞肺癌 (SCLC) 的有效治疗选择有限.
- 对于SCLC,迫切需要新的治疗点.
- 素家族成员11 (KIF11) 作为潜在的SCLC标被探索.
研究的目的:
- 研究KIF11在SCLC中的作用.
- 评估KIF11抑制作为SCLC的治疗策略.
主要方法:
- 对SCLC组织中KIF11的公开基因表达数据的分析.
- 在SCLC细胞系中使用RNA干扰和小分子抑制剂 (SB743921) 抑制KIF11 (Lu-135,NCI-H69).
- 评估KIF11和/或BCL2L1抑制后的细胞周期进展,生长抑制和细胞活力.
主要成果:
- 与正常肺组织相比,SCLC组织中的KIF11mRNA表达显著升高.
- 抑制KIF11导致G2/M阶段细胞周期停止,并在SCLC细胞系中完全抑制生长.
- 双重抑制KIF11和BCL2L1显著降低了SCLC细胞活力.
结论:
- 在SCLC细胞的生存和繁殖过程中,它们对KIF11具有关键的依赖性.
- 抑制KIF11代表了对SCLC治疗的潜在新疗法策略.
- 联合KIF11和BCL2L1抑制可能在SCLC治疗中提供更高的疗效.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
